A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
Article in ESMO Open (April 2024)
The most recent citing publications are shown below. View all 729 publications that cite this research output on Dimensions.
Article in ESMO Open (April 2024)
Article in PLOS ONE (April 2024)
Article in Cancer Research (April 2024)